Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 39NET 27Gastrointestinal 6Thoracic 3CNS 3Head & Neck 2Gynecologic 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 2267Lung Neoplasms 1050Small Cell Lung Carcinoma 404Adenocarcinoma of Lung 155Mesothelioma, Malignant 120Breast Neoplasms 110Neoplasms 106Brain Neoplasms 101Neoplasm Metastasis 95Melanoma 72Mesothelioma 70NSCLC 69Colorectal Neoplasms 69Adenocarcinoma, Bronchiolo-Alveolar 56Thymoma 53Pancreatic Neoplasms 52Head and Neck Neoplasms 47Ovarian Neoplasms 46Carcinoma, Renal Cell 43Carcinoma 39Stomach Neoplasms 36Prostatic Neoplasms 36Sarcoma 35Esophageal Neoplasms 35Uterine Cervical Neoplasms 34Squamous Cell Carcinoma of Head and Neck 34Adenocarcinoma 34Pleural Effusion, Malignant 33Recurrence 27Urinary Bladder Neoplasms 26

Interventions

zimberelimab 1pembrolizumab 1ganitumab 1conatumumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Carcinoid Tumor × Thoracic × Clear all
NCT06790706 2025-10-06

IMMUNORARE5

Hospices Civils de Lyon

Phase 2 Recruiting
154 enrolled
EndocrineGastrointestinalGynecologicHead & NeckNETThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Thymoma, Gestational Trophoblastic Disease, Thyroid Carcinoma, Anaplastic

NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡